10.5281/zenodo.4527054
https://zenodo.org/records/4527054
oai:zenodo.org:4527054
Calancea, Valentin
Valentin
Calancea
0000-0002-8643-367X
Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova
Matcovschi, Sergiu
Sergiu
Matcovschi
0000-0003-1623-930X
Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova
Nichita, Svetlana
Svetlana
Nichita
0000-0002-7614-8330
Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova
Martiniuc, Constantin
Constantin
Martiniuc
0000-0002-2724-6567
Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova
Opportunities of Fenspiride anti-inflammatory therapy in patients with chronic obstructive pulmonary disease
Zenodo
2021
chronic obstructive pulmonary disease
pulmonary ventilation
exercise tolerance
2021-02-15
eng
10.5281/zenodo.4527053
Creative Commons Attribution 4.0 International
Background: Currently, bronchodilator medication recommended in the basic treatment of stable chronic obstructive pulmonary disease (COPD) does not have direct anti-inflammatory properties. According to recent researches Fenspiride has a multi-functional effect on various links of the inflammatory process in the respiratory tract. The purpose of this study was to assess the clinical efficacy and safety of Fenspiride in the treatment of COPD in remission.
Material and methods: The research was performed on a group of 42 patients with COPD in stages GOLD 1 and GOLD 2. Depending on the treatment applied, patients were divided into 2 groups. The first group received Fenspiride with basic treatment and the second group only basic treatment. The main symptoms, pulmonary ventilation indexes and exercise tolerance were assessed in all patients.
Results: The results obtained showed that Fenspiride improves the symptoms of the disease, pulmonary ventilation and increases patients' exercise tolerance.
Conclusion: Fenspiride is an effective and harmless remedy that can be used for the anti-inflammatory treatment of stable COPD in stages GOLD I and II.